Oragenics (OGEN) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-32188
Entity Registrant Name	ORAGENICS, INC.
Entity Central Index Key	0001174940
Entity Tax Identification Number	59-3410522
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	4902 Eisenhower Blvd.
Entity Address, Address Line Two	Suite 125
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33634
City Area Code	813
Local Phone Number	286-7900
Title of 12(b) Security	Common Stock
Trading Symbol	OGEN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,024,657

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,158,340	$ 11,426,785
Prepaid expenses and other current assets	2,544,713	2,844,798
Total current assets	11,703,053	14,271,583
Property and equipment, net	109,759	121,062
Deposit	17,940	17,940
Operating lease right-of-use assets	298,724	347,440
Total assets	12,129,476	14,758,025
Current liabilities:
Accounts payable and accrued expenses	1,470,505	1,124,197
Short-term notes payable	107,890	267,640
Operating lease liabilities	202,187	204,447
Total current liabilities	1,780,582	1,596,284
Long-term liabilities
Operating lease liabilities	104,463	152,439
Total long-term liabilities	104,463	152,439
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	1,592,723	1,592,723
Common stock, $0.001 par value; 4,166,666 shares authorized 2,024,657 and 2,024,657 shares issued and outstanding at March 31, 2023 and December 31, 2022	2,025	2,025
Additional paid-in capital	197,057,037	196,977,071
Accumulated deficit	(188,407,354)	(185,562,517)
Total shareholders’ equity	10,244,431	13,009,302
Total liabilities and shareholders’ equity	$ 12,129,476	$ 14,758,025

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	4,166,666	4,166,666
Common stock, shares issued	2,024,657	2,024,657
Common stock, shares outstanding	2,024,657	2,024,657
Series A Preferred Stock [Member]
Preferred stock, shares issued	5,417,000	5,417,000
Preferred stock, shares outstanding	5,417,000	5,417,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	4,050,000	4,050,000
Preferred stock, shares outstanding	4,050,000	4,050,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Grant revenue	$ 17,024	$ 15,083
Operating expenses:
Research and development	1,672,576	3,293,661
General and administrative	1,249,263	1,331,549
Total operating expenses	2,921,839	4,625,210
Loss from operations	(2,904,815)	(4,610,127)
Other income (expense):
Interest income	62,201	11,906
Interest expense	(3,347)	(3,246)
Local business tax		(490)
Miscellaneous income	1,124	10,964
Total other income, net	59,978	19,134
Loss before income taxes	(2,844,837)	(4,590,993)
Income tax benefit
Net loss	$ (2,844,837)	$ (4,590,993)
Basic and diluted net loss per share	$ (1.41)	$ (2.29)
Shares used to compute basic and diluted net loss per share	2,024,766	2,002,946

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 2,003	$ 2,656,713	$ 195,101,611	$ (171,274,128)	$ 26,486,199
Beginning balance, shares at Dec. 31, 2021	2,002,946	16,017,000
Compensation expense relating to option issuances			90,247		90,247
Net loss				(4,590,993)	(4,590,993)
Ending balance, value at Mar. 31, 2022	$ 2,003	$ 2,656,713	195,191,858	(175,865,121)	21,985,453
Ending balance, shares at Mar. 31, 2022	2,002,946	16,017,000
Beginning balance, value at Dec. 31, 2022	$ 2,025	$ 1,592,723	196,977,071	(185,562,517)	13,009,302
Beginning balance, shares at Dec. 31, 2022	2,024,657	9,467,000
Compensation expense relating to option issuances			79,966		79,966
Net loss				(2,844,837)	(2,844,837)
Ending balance, value at Mar. 31, 2023	$ 2,025	$ 1,592,723	$ 197,057,037	$ (188,407,354)	$ 10,244,431
Ending balance, shares at Mar. 31, 2023	2,024,657	9,467,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,844,837)	$ (4,590,993)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,303	8,468
Gain on sale of property and equipment		(10,964)
Stock-based compensation expense	79,966	90,247
Changes in operating assets and liabilities:
Other receivables		6,987
Prepaid expenses and other current assets	300,085	(1,287,175)
Operating Lease Right of Use Assets	48,716	45,921	$ 45,921
Accounts payable and accrued expenses	346,309	147,884
Change in Operating Lease Liabilities	(50,237)	(47,327)	47,327
Net cash used in operating activities	(2,108,695)	(5,636,952)
Cash flows from investing activities:
Proceeds from sale of property and equipment		12,000
Purchase of property and equipment		(87,047)
Net cash used in investing activities		(75,047)
Cash flows from financing activities:
Payments on short-term notes payable	(159,750)	(181,241)
Net cash provided by (used in) financing activities	(159,750)	(181,241)
Net increase (decrease) in cash and cash equivalents	(2,268,445)	(5,893,240)
Cash and cash equivalents at beginning of period	11,426,785	27,265,703	27,265,703
Cash and cash equivalents at end of period	9,158,340	21,372,463	$ 11,426,785
Supplemental disclosure of cash flow information:
Interest paid	$ 3,347	$ 3,246

Organization

Organization	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (the “Company” or “we”) is focused on the development of the NT-CoV2-1 intranasal vaccine candidate to combat the novel Severe Acute Respiratory Syndrome coronavirus (“SARS-CoV-2”) and further development of effective treatments for novel antibiotics against infectious disease.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited interim consolidated financial statements as of March 31, 2023 and December 31, 2022 (audited) and three months ended March 31, 2023 and 2022, have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim consolidated financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. In the opinion of management, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ended March 31, 2023, are not necessarily indicative of the results of operations that may be expected for the year ended December 31, 2023, or any future period. Prior Period Restatements On April 4, 2023 the Company’s management and Audit Committee of the Company’s Board of Directors concluded that the unaudited consolidated financial statements for the three-month period ended March 31, 2022 should be restated and should no longer be relied upon. Management reviewed the terms and conditions of the Company’s contracts and the payments and concluded that during the three-month period ending March 31, 2022 amounts were paid as part of a prepayment arrangement. Management reviewed Accounting Standards Codification Topic 730 Research and Development guidance related to recording initial upfront payments to vendors; and determined that the unaudited consolidated financial statements originally reported for the three-month period ended March 31, 2022 classified as research and development expense on the unaudited consolidated statement of operations that should be classified as prepaid expense on the Company’s unaudited consolidated balance sheet. On April 14, 2023 the Company filed Amendment 1 on Form 10-Q/A with the SEC. Amendment 1 was filed for the sole purpose of restating certain financial statements included in the Original Form 10-Q. When referencing prior period comparisons for the three-month period ended March 31, 2022 in this Form 10-Q for the three-month period ended March 31, 2023 the financial information reflects the restated financials as reported in Amendment 1. Going Concern Consideration These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 17, 2023. The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $ 2,844,837 2,108,695 188,407,354 The Company expects to incur substantial expenditures to further develop its technologies. The Company believes the working capital at March 31, 2023 will be sufficient to meet the business objectives as presently structured through the fourth quarter of 2023. As such, there is substantial doubt that we can continue as a going concern beyond that date. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs and forego future development and other opportunities.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc.(“NTI”). All intercompany balances and transactions have been eliminated. New Accounting Standards There are no additional accounting pronouncements issued or effective during the three months ended March 31, 2023, that have had, or are expected to have, a material impact on our consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations. Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments to the Consolidated Balance Sheet and Statement of Cash Flows for th e three-month period ended March 31, 2022 were as follows: ● Deposits of $ 17,940 ● Changes in Operating Lease Right of Use Assets of $ 45,921 ● Changes in Operating Lease Liabilities of ($ 47,327 Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes Option Pricing Model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, or warrants do not vest at the grant date they are subject to forfeiture. Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur. Warrants The Company used the Black-Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of March 31, 2023, the uninsured portion of this balance was $ 8,908,340 11,176,785 Grant Revenue Grant revenues are derived from a small business innovation research grant in the amount of $ 250,000

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	4. Property and Equipment, net Property and equipment, net consists of the following as of March 31, 2023 and December 31, 2022: Summary of Property and Equipment, Net March 31, 2023 December 31, 2022 Furniture and fixtures $ 20,742 $ 20,742 Laboratory equipment 676,744 676,744 Leasehold improvements 487,871 487,871 Office and computer equipment 298,944 298,944 Property and equipment, gross 1,484,301 1,484,301 Accumulated depreciation and amortization (1,374,542 ) (1,363,239 ) Property and equipment, net $ 109,759 $ 121,062 Depreciation and amortization expense for the three months ended March 31, 2023 and March 31, 2022 was $ 11,303 8,468

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	5. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following as of March 31, 2023 and December 31, 2022: Summary of Accounts Payable and Accrued Expenses March 31, 2023 December 31, 2022 Accounts payable trade $ 939,013 $ 246,690 Accrued Expense 488,372 812,861 Professional fees - 31,101 Vacation 43,120 33,545 Total accounts payable and accrued expenses $ 1,470,505 $ 1,124,197

Short-Term Notes Payable

Short-Term Notes Payable	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Short-Term Notes Payable	6. Short-Term Notes Payable The Company had the following short-term notes payable as of March 31, 2023 and December 31, 2022: Summary of Short-Term Notes payable March 31, 2023 December 31, 2022 Directors’ and officers’ liability insurance financing of $ 528,429 600,169 54,366 61,496 6.24 5.34 May 24, 2023 May 24, 2022 $ 107,890 $ 267,640 Directors’ and officers’ liability $ 107,890 $ 267,640 The Company also maintains a product liability insurance policy which has been renewed in subsequent periods without premium financing.

Prepaid Expense and Other Curre

Prepaid Expense and Other Current Assets	3 Months Ended
	Mar. 31, 2023
Prepaid Expense And Other Current Assets
Prepaid Expense and Other Current Assets	7. Prepaid Expense and Other Current Assets Schedule of Prepaid Expense and Other Current Assets at March 31, 2023 and December 31, 2022: Schedule of Prepaid Expense and Other Current Assets March 31, 2023 December 31, 2022 Prepaid Research and Development Expense 2,256,983 2,471,809 Prepaid Insurance 212,730 372,989 Prepaid Financing costs 75,000 - Total 2,544,713 2,844,798 As of March 31, 2023 and December 31, 2022, the Company had $ 2,544,713 2,844,798 in prepaid expenses 2.3 0.08 0.2

Shareholders_ Equity

Shareholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Shareholders’ Equity	8. Shareholders’ Equity Common Stock Approval of a Reverse Stock Split On December 22, 2022, the Board of Directors approved an amendment to our Amended and Restated Articles of Incorporation to effect a reverse stock split of our common stock by a ratio of one for sixty Shares issued under At-The-Market (“ATM”) program For the three-month periods ended March 31, 2022 and 2023 the Company did not issue any shares of common stock under its ATM program. During the six- and nine- month periods ending June 30, 2022 and September 30, 2022 the Company did not issue any shares of common stock under its ATM program. During the three-month period ended December 31, 2022, the Company issued 6,544 72,000 On December 19, 2022, the Company sent written notice of termination to A.G.P./Alliance Global Partners (“AGP”), pursuant to the terms of the Company’s Sales Agreement with AGP in connection with the Company’s ATM Program. The termination took effect on December 29, 2022. As a result of the termination, the Company will not, and during the three months ended March 31, 2023 did not, consummate any further sale of its common stock through the AGP Sales Agreement. On February 24, 2023 the Company entered into an ATM with Ladenburg Thalmann & Co. Inc (“Ladenburg”) to sell shares of its common stock. The Company intends to use the proceeds from the ATM to continue funding its pre-clinical development of its SARS-CoV-2 vaccine candidates, Terra CoV-2 and NT-CoV2-1 and its lantibiotics program and for the general corporate purposes, including capital expenditures, working capital, and research and development activities. Other Share Issuances During the three-month periods ended March 31, 2022 and 2023 the Company issued no During the three-month period ended September 30, 2022 the holders of 4,000,000 2,550,000 15,000 During the twelve-months ended December 31, 2022, the Company issued 13,019 363,139 Preferred Stock Issuance of Series A Convertible Preferred Stock Financing In May of 2017 we entered into a securities purchase agreement to sell up to $ 3 The full $ 3 17,742 The warrants have a term of seven years from the date of issuance and have an exercise price of $186.00 per share The Series A Preferred Stock also includes certain demand registration rights, piggyback registration rights and liquidation preference rights. On May 10, 2017, we filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Florida. Except as otherwise required by law, as long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (c) increase the number of authorized shares of Series A Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. Upon any liquidation, dissolution or winding-up by us, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of Series A Preferred Stock shall be entitled to receive out of the assets, the greater of (i) the product of the number of shares of Series A Preferred Stock then held by such holder, multiplied by the Original Issue Price; and (ii) the amount that would be payable to such holder in the Liquidation in respect of Common Stock issuable upon conversion of such shares of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock were converted into Common Stock immediately prior to the Liquidation. The Series A Preferred Stock is classified as permanent equity. The Series B Non-Voting, Convertible Preferred Stock Financing On November 8, 2017, we completed a private placement of $ 3.3 The full $ 3.3 million of Series B Convertible Preferred Stock, and after giving effect to the reverse stock splits and the previous conversions, is convertible into 13,500 shares of our common stock, based on a conversion of one share of Series B Preferred Stock into two shares of Common Stock. The purchase price per share of the Series B Preferred Stock is represented by $ 150.00 per share of the Common Stock on an as converted basis. In addition, and after giving effect to the reverse stock split, we issued to the investors in the private placement accompanying common stock purchase warrants to purchase an aggregate of approximately 17,742 shares of Common Stock. The warrants have a term of seven years from the date of issuance, and after giving effect to the reverse stock split, have an exercise price of $ 186.00 per share. In connection with the Series B Preferred Financing, we filed a Certificate of Designation and Rights of Series B Convertible Preferred Stock with the Secretary of State of the State of Florida, to be effective November 8, 2017. Except as otherwise required by law, the Series B Preferred Stock shall have no voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Certificate of Designation, (b) amend its articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (c) increase the number of authorized shares of Series B Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank (i) on par with the Common Stock and Series A Preferred Stock and junior to Series C Preferred Stock as to dividend rights and (ii) junior to Series C Preferred Stock, on par with Series A Preferred Stock and senior to the Common Stock as to distribution of assets upon liquidation, dissolution or winding-up by us, whether voluntary or involuntary. Upon any liquidation, dissolution or winding-up by us, whether voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to receive out of the assets, after payment to the holders of Series C Preferred Stock but on par with the holders of Series A Preferred Stock and in preference to the holders of the Common Stock, an amount of cash equal to the greater of (i) the product of the number of shares of Series B Preferred Stock then held by such holder, multiplied by the Original Issue Price; and (ii) the amount that would be payable to such holder in the Liquidation in respect of Common Stock issuable upon conversion of such shares of Series B Preferred Stock if all outstanding shares of Series B Preferred Stock were converted into Common Stock immediately prior to the Liquidation. The Series B Preferred Stock is classified as permanent equity.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2023
Warrants
Warrants	9. Warrants The Company’s outstanding and exercisable warrants as of March 31, 2023 are presented below: Schedule of Warrants Outstanding and Exercisable Exercise Price Total Warrants Outstanding Exercisable Warrants Outstanding Expiration Date $ 120.00 15,000 15,000 4/10/2023 $ 54.00 32,033 32,033 3/25/2024 $ 186.00 5,135 5,135 5/10/2024 $ 186.00 6,694 6,694 7/25/2024 $ 186.00 10,888 10,888 11/8/2024 $ 75.00 153,334 153,334 5/1/2025 $ 60.00 52,911 52,911 7/17/2025 275,995 275,995 All outstanding warrants are classified as equity on the Company’s Consolidated Balance Sheets.

Stock Compensation Plan

Stock Compensation Plan	3 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Stock Compensation Plan	10. Stock Compensation Plan On February 25, 2022, the Company held its 2020 Annual Meeting. At the 2020 Annual Meeting, the shareholders of the Company approved and ratified the Company’s 2021 Equity Incentive Plan (the “2021 Incentive Plan”), which is a successor to the 2012 Incentive Plan. The 2021 Incentive Plan provides the aggregate number of shares of Common Stock that may be issued under the 2021 Plan will not exceed the sum of (i) 166,667 new shares, (ii) the number of shares remaining available for the grant of new awards under the 2012 Incentive Plan as of immediately prior to the effective date of the 2021 Incentive Plan, and (iii) certain shares subject to outstanding awards granted under the 2012 Incentive Plan that may become available for issuance under the 2021 Incentive Plan, as such shares become available from time to time. As of December 31, 2022, an aggregate of 139,091 shares of common stock are covered by outstanding option awards and 148,455 shares of common stock are available for future awards under the 2021 Incentive Plan. Options are granted at the fair market value of the Company’s stock on the date of grant. Options can vest either immediately or over a period of up to three years 10 Total compensation cost related to stock options was approximately $ 79,966 90,247 182,475 During the three-months ended March 31, 2023, the Company granted 7,000 3.92 per share of common stock Summary of Assumptions Used to Estimate the Fair Value of Stock Options Granted Three-months ended March 31, 2023 Risk free interest rate 4.0 % Expected volatility of common stock 143.0 % Dividend yield 0.0 % Expected life of options 10

License Agreements

License Agreements	3 Months Ended
	Mar. 31, 2023
License Agreements
License Agreements	11. License Agreements Inspirevax License On February 23, 2023, the Company entered into a Commercial License Agreement (the “License Agreement”) with Inspirevax Inc. (“Inspirevax”) pursuant to which Inspirevax granted the Company an exclusive worldwide license to use Inspirevax’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of Inspirevax (the “Inspirevax Technologies”) relating to its novel lipid-protein based intranasal adjuvants, to make, research, and develop an intra-nasal vaccine in combination with an antigen (“Combination Product”) to be used in an intranasal vaccine for use against diseases caused by coronaviruses and any genetic variants thereof to be sold by us. The Company agreed to pay in consideration for the License Agreement an upfront signing fee and to certain milestone payment obligations. NIH License Through NTI, the Company is a party to a Patent License and Biological Materials License Agreement (the “License Agreement” or “NIH License”), dated March 23, 2020, with the United States Department of Health and Human Services (the “HHS”), as represented by the National Institute of Allergy and Infectious Diseases (“NIAID”), an Institute within the National Institutes of Health (“NIH”). Under the terms of the License Agreement, the Company holds a nonexclusive, worldwide license to certain specified patent rights (including patent applications, provisional patent applications and Patent Cooperation Treaty (“PCT”) patent applications) and biological materials relating to the use of pre-fusion coronavirus spike proteins to exploit products (“Licensed Products”) and practice processes (“Licensed Processes”) that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for SARS-CoV-2. NRC License On July 26, 2021, the Company entered into a non-exclusive Technology License Agreement (the “License Agreement”) with the National Research Council of Canada (“NRC”) pursuant to which the NRC grants to the Company a license to use NRC’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of the NRC (the “NRC Technologies”) relating to the derivatives of CHO 2353 TM ”)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Additional Consideration−Noachis Terra Inc.(“NTI”) Acquisition. In connection with the Company’s acquisition of NTI, the Company is obligated to pay the former sole shareholder of NTI contingent consideration based upon the exercise of certain of the Company’s outstanding warrants as follows: (i) twenty percent ( 20 45.00 54.00 45 60.00 The Company’s previously issued warrants carrying an exercise price of $45.00 have expired by their terms. As a result, no additional consideration will be due to the former sole shareholder of NTI relating to these warrants. During the three months ended March 31, 2021, 41,210 6,000 60.00 35,210 54.00 As of the three-month period ended March 31, 2023, there are 32,033 warrants outstanding carrying an exercise price of $54.00 that expire on March 25, 2024. Inspirevax License As consideration for the License Agreement with Inspirevax the Company will be subject to certain milestone payments related to various events including but not limited to: (a) the Company’s decision for an appropriate nasal spray device, (b) phase 2a and 2b/3 clinical trials and patient participation, (c) certain license applications submitted to the FDA; (d) certain filing events for marketing authorizations out of the United States; and (e) certain metrics for sales within the United States, Europe and other countries or regions. Additionally, the Company is required to pay to Inspirevax certain royalties based upon net sales and subject to revenue limitations at which time the royalty amount will decrease. The amount of the milestone obligations could range from $ 0.1 million 7.25 million Unless terminated earlier, the License Agreement will terminate the later of (i) twenty ( 20 NIH License Under the terms of the NIH License Agreement, the NIAID is entitled to receive lump sum nonrefundable minimum annual royalties, which increase in the year after the first commercial sale of any Licensed Products or the practice of any Licensed Processes, as well as lump sum benchmark royalties following our completion of certain commercial development and sales-related benchmarks. The NIH is entitled to receive earned royalties on the annual net sales of Licensed Products and the practice of any Licensed Processes (subject to certain reductions), at certain low- to mid-single digit royalty rates, which rates vary based on the total amount of annual net sales and the geographic market in which those sales occur. We must provide regular written reports to the NIAID on the development status of and royalty payments relating to the Licensed Products and the Licensed Processes. The License Agreement will expire upon (a) twenty ( 20 NRC License As consideration for the grant of the NRC license, the Company will pay to the NRC an annual (low five digits) license fee, with the initial portion of the fee covering the first three years of the license (already paid). Additionally, we will pay certain milestone payments (a) upon transfer of each Stable Cell listed in the Agreement and (b) with regard to each of the first three Products, (i) upon submission of the Investigational New Drug application (IND) related thereto, (ii) upon dosing the first patient in a Phase 1 or Phase 2 clinical trial, (iii) upon dosing the first patient in a Phase 3 clinical trial and (iv) upon first regulatory approval. Milestone payments range from the low five digits to high six digits. In addition, Oragenics will pay a low single-digit royalty to the NRC for the sale of Products, based on sales revenue, commencing after the first commercial sale. Pursuant to the License Agreement, the NRC is required to bear the responsibility and pay the costs to obtain and maintain patents related to the NRC Technologies in certain countries, additional countries may be requested by us at our expense. In addition, the Company is required to provide certain indemnifications to the NRC and its employees. Unless terminated earlier, the License Agreement will terminate twenty ( 20

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases
Leases	13. Leases Lab Facility-Alachua 12,870 13,338 41,426 Corporate Office-Tampa. In November of 2016, the Company entered into an amendment for the leased office space for corporate personnel located in Tampa, FL. The amended lease is for approximately 2,207 4,944 February 29, 2024 16,700 Schedule of Other Information Related to Leases For the Three For the Twelve Weighted Average Remaining Lease Term In Years Operating leases 1.46 1.72 Weighted Average Discount Rate Operating leases 5.70 % 5.78 % Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2023 164,535 2024 156,605 2025 - Total $ 321,140 Less: effect of discounting (14,491 ) Present value of lease liabilities $ 306,649 The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Three Months Ended March 31, 2023 For the Three Months Ended March 31, 2022 Operating lease cost $ 57,755 $ 57,129 Short-term lease cost - 1,634 Total lease cost $ 57,755 $ 58,763 Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Three Months Ended March 31, 2023 For the Three Months Ended March 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (59,274 ) $ (58,535 )

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc.(“NTI”). All intercompany balances and transactions have been eliminated.
New Accounting Standards	New Accounting Standards There are no additional accounting pronouncements issued or effective during the three months ended March 31, 2023, that have had, or are expected to have, a material impact on our consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations.
Reclassification	Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments to the Consolidated Balance Sheet and Statement of Cash Flows for th e three-month period ended March 31, 2022 were as follows: ● Deposits of $ 17,940 ● Changes in Operating Lease Right of Use Assets of $ 45,921 ● Changes in Operating Lease Liabilities of ($ 47,327
Stock-Based Payment Arrangements	Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes Option Pricing Model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, or warrants do not vest at the grant date they are subject to forfeiture.
Stock-Based Compensation	Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur.
Warrants	Warrants The Company used the Black-Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.
Concentrations	Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of March 31, 2023, the uninsured portion of this balance was $ 8,908,340 11,176,785
Grant Revenue	Grant Revenue Grant revenues are derived from a small business innovation research grant in the amount of $ 250,000

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consists of the following as of March 31, 2023 and December 31, 2022: Summary of Property and Equipment, Net March 31, 2023 December 31, 2022 Furniture and fixtures $ 20,742 $ 20,742 Laboratory equipment 676,744 676,744 Leasehold improvements 487,871 487,871 Office and computer equipment 298,944 298,944 Property and equipment, gross 1,484,301 1,484,301 Accumulated depreciation and amortization (1,374,542 ) (1,363,239 ) Property and equipment, net $ 109,759 $ 121,062

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following as of March 31, 2023 and December 31, 2022: Summary of Accounts Payable and Accrued Expenses March 31, 2023 December 31, 2022 Accounts payable trade $ 939,013 $ 246,690 Accrued Expense 488,372 812,861 Professional fees - 31,101 Vacation 43,120 33,545 Total accounts payable and accrued expenses $ 1,470,505 $ 1,124,197

Short-Term Notes Payable (Table

Short-Term Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Summary of Short-Term Notes payable	The Company had the following short-term notes payable as of March 31, 2023 and December 31, 2022: Summary of Short-Term Notes payable March 31, 2023 December 31, 2022 Directors’ and officers’ liability insurance financing of $ 528,429 600,169 54,366 61,496 6.24 5.34 May 24, 2023 May 24, 2022 $ 107,890 $ 267,640 Directors’ and officers’ liability $ 107,890 $ 267,640

Prepaid Expense and Other Cur_2

Prepaid Expense and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expense and Other Current Assets	Schedule of Prepaid Expense and Other Current Assets at March 31, 2023 and December 31, 2022: Schedule of Prepaid Expense and Other Current Assets March 31, 2023 December 31, 2022 Prepaid Research and Development Expense 2,256,983 2,471,809 Prepaid Insurance 212,730 372,989 Prepaid Financing costs 75,000 - Total 2,544,713 2,844,798

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Warrants
Schedule of Warrants Outstanding and Exercisable	The Company’s outstanding and exercisable warrants as of March 31, 2023 are presented below: Schedule of Warrants Outstanding and Exercisable Exercise Price Total Warrants Outstanding Exercisable Warrants Outstanding Expiration Date $ 120.00 15,000 15,000 4/10/2023 $ 54.00 32,033 32,033 3/25/2024 $ 186.00 5,135 5,135 5/10/2024 $ 186.00 6,694 6,694 7/25/2024 $ 186.00 10,888 10,888 11/8/2024 $ 75.00 153,334 153,334 5/1/2025 $ 60.00 52,911 52,911 7/17/2025 275,995 275,995

Stock Compensation Plan (Tables

Stock Compensation Plan (Tables)	3 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Summary of Assumptions Used to Estimate the Fair Value of Stock Options Granted	Summary of Assumptions Used to Estimate the Fair Value of Stock Options Granted Three-months ended March 31, 2023 Risk free interest rate 4.0 % Expected volatility of common stock 143.0 % Dividend yield 0.0 % Expected life of options 10

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases
Schedule of Other Information Related to Leases	Schedule of Other Information Related to Leases For the Three For the Twelve Weighted Average Remaining Lease Term In Years Operating leases 1.46 1.72 Weighted Average Discount Rate Operating leases 5.70 % 5.78 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2023 164,535 2024 156,605 2025 - Total $ 321,140 Less: effect of discounting (14,491 ) Present value of lease liabilities $ 306,649
Schedule of Cost Component of Operating Leases	The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Three Months Ended March 31, 2023 For the Three Months Ended March 31, 2022 Operating lease cost $ 57,755 $ 57,129 Short-term lease cost - 1,634 Total lease cost $ 57,755 $ 58,763
Schedule of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Three Months Ended March 31, 2023 For the Three Months Ended March 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (59,274 ) $ (58,535 )

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Net loss	$ 2,844,837	$ 4,590,993
Cash used in operating activities	2,108,695	$ 5,636,952
Accumulated deficit	$ 188,407,354		$ 185,562,517

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Product Information [Line Items]
Deposits	$ 17,940	$ 17,940	$ 17,940
Operating lease right of use assets	48,716	45,921	45,921
Operating lease liability	(50,237)	(47,327)	47,327
Uninsured portion of balance	8,908,340		$ 11,176,785
Revenue	17,024	$ 15,083
Grant [Member]
Product Information [Line Items]
Revenue	$ 250,000

Summary of Property and Equipme

Summary of Property and Equipment, Net (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,484,301	$ 1,484,301
Accumulated depreciation and amortization	(1,374,542)	(1,363,239)
Property and equipment, net	109,759	121,062
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,742	20,742
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	676,744	676,744
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	487,871	487,871
Officeand Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 298,944	$ 298,944

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 11,303	$ 8,468

Summary of Accounts Payable and

Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable trade	$ 939,013	$ 246,690
Accrued Expense	488,372	812,861
Professional fees		31,101
Vacation	43,120	33,545
Total accounts payable and accrued expenses	$ 1,470,505	$ 1,124,197

Summary of Short-Term Notes pay

Summary of Short-Term Notes payable (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Directors’ and officers’ liability	$ 107,890	$ 267,640

Summary of Short-Term Notes p_2

Summary of Short-Term Notes payable (Details) (Parenthetical) - Directors and Officers Liability [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Director [Member]
Debt Instrument, Face Amount	$ 528,429
Debt Instrument, Periodic Payment	$ 54,366
Debt Instrument, Interest Rate, Stated Percentage	6.24%
Debt Instrument, Maturity Date	May 24, 2023
Officers [Member]
Debt Instrument, Face Amount	$ 600,169
Debt Instrument, Periodic Payment	$ 61,496
Debt Instrument, Interest Rate, Stated Percentage	5.34%
Debt Instrument, Maturity Date	May 24, 2022

Schedule of Prepaid Expense and

Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Prepaid Research and Development Expense	$ 2,256,983	$ 2,471,809
Prepaid Insurance	212,730	372,989
Prepaid Financing costs	75,000
Total	$ 2,544,713	$ 2,844,798

Prepaid Expense and Other Cur_3

Prepaid Expense and Other Current Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Prepaid Expense and Other Assets, Current	$ 2,544,713		$ 2,844,798
Research and Development Expense	1,672,576	$ 3,293,661
Prepaid financing costs	75,000
Prepaid Insurance	212,730		$ 372,989
Third Party Vendor [Member]
Defined Benefit Plan Disclosure [Line Items]
Research and Development Expense	$ 2,300,000

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended				12 Months Ended
	Dec. 22, 2022	Nov. 08, 2017	May 31, 2017	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Reverse Stock Split	reverse stock split of our common stock by a ratio of one for sixty
Number of common stock issued				0			0
Stock Issued During Period, Shares, Conversion of Units		13,500
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares converted						4,000,000
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares converted						2,550,000
Series A Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants description			The warrants have a term of seven years from the date of issuance and have an exercise price of $186.00 per share
Series A Convertible Preferred Stock [Member] | First Closing [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			17,742
Series B Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred Stock, Convertible, Conversion Price		$ 150
Series B Convertible Preferred Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred Stock, Conversion Basis		The full
Proceeds from Issuance of Private Placement		$ 3,300,000
Securities Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Three Accredited Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock			$ 3,000,000
Preferred Stock, Conversion Basis			The full $3 million of Preferred Stock, after giving effect to the reverse stock splits and previous conversions, is convertible into 9,029 shares of our common stock based on a fixed conversion price of $150.00 per share on an as-converted basis
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued								13,019
Number of shares issued during conversion						15,000
Proceeds from Stock Options Exercised								$ 363,139
Common Stock [Member] | ATM Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued					6,544
Proceeds from Issuance of Common Stock					$ 72,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									41,210
Warrant [Member] | Series B Convertible Preferred Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		17,742
Warrants and Rights Outstanding, Term		7 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 186

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	Mar. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants Outstanding	275,995
Warrants Exercisable	275,995
Range One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 120
Warrants Outstanding	15,000
Warrants Exercisable	15,000
Warrants and Rights Outstanding, Maturity Date	Apr. 10, 2023
Range Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 54
Warrants Outstanding	32,033
Warrants Exercisable	32,033
Warrants and Rights Outstanding, Maturity Date	Mar. 25, 2024
Range Three [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 186
Warrants Outstanding	5,135
Warrants Exercisable	5,135
Warrants and Rights Outstanding, Maturity Date	May 10, 2024
Range Four [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 186
Warrants Outstanding	6,694
Warrants Exercisable	6,694
Warrants and Rights Outstanding, Maturity Date	Jul. 25, 2024
Range Five [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 186
Warrants Outstanding	10,888
Warrants Exercisable	10,888
Warrants and Rights Outstanding, Maturity Date	Nov. 08, 2024
Range Six [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 75
Warrants Outstanding	153,334
Warrants Exercisable	153,334
Warrants and Rights Outstanding, Maturity Date	May 01, 2025
Range Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 60
Warrants Outstanding	52,911
Warrants Exercisable	52,911
Warrants and Rights Outstanding, Maturity Date	Jul. 17, 2025

Summary of Assumptions Used to

Summary of Assumptions Used to Estimate the Fair Value of Stock Options Granted (Details)	3 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Risk free interest rate	4%
Expected volatility of common stock	143%
Dividend yield	0%
Expective life of options	10 years

Stock Compensation Plan (Detail

Stock Compensation Plan (Details Narrative) - USD ($)		3 Months Ended
	Feb. 25, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		0	0
Share-Based Payment Arrangement, Noncash Expense		$ 79,966	$ 90,247
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 182,475
Chief Financial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted		7,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 3.92
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues	166,667
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number				139,091
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant				148,455
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period		10 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	May 01, 2020	Mar. 31, 2023	Mar. 31, 2021
Range One [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 120
Range Two [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 54
Minimum [Member]
Loss Contingencies [Line Items]
Milestone obligations amount		$ 100
Maximum [Member]
Loss Contingencies [Line Items]
Milestone obligations amount		$ 7,250
Warrant [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			41,210
Warrant [Member] | Range One [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			6,000
Warrant [Member] | Range Two [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 54
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			35,210
Stock Purchase Agreement [Member] | Noachis Terra Inc. [Member] | Warrant [Member]
Loss Contingencies [Line Items]
Percentage of warrant exercise	20%
Warrants exercise term description	The Company’s previously issued warrants carrying an exercise price of $45.00 have expired by their terms. As a result, no additional consideration will be due to the former sole shareholder of NTI relating to these warrants.
Stock Purchase Agreement [Member] | Noachis Terra Inc. [Member] | Warrant [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 45
Stock Purchase Agreement [Member] | Noachis Terra Inc. [Member] | Warrant [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 54
Stock Purchase Agreement [Member] | Noachis Terra Inc. [Member] | Warrant One [Member]
Loss Contingencies [Line Items]
Percentage of warrant exercise	45%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 60
Inspirevax License Agreement [Member]
Loss Contingencies [Line Items]
Agreement expiration term		20 years
NIH License Agreement [Member]
Loss Contingencies [Line Items]
Agreement expiration term		20 years
NRC License Agreement [Member]
Loss Contingencies [Line Items]
Agreement expiration term		20 years

Schedule of Other Information R

Schedule of Other Information Related to Leases (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases
Operating Lease, Weighted Average Remaining Lease Term	1 year 5 months 15 days	1 year 8 months 19 days
Weighted Average Discount Rate, Operating leases	5.70%	5.78%

Schedule of Maturities of Opera

Schedule of Maturities of Operating Lease Liabilities (Details)	Mar. 31, 2023 USD ($)
Leases
2023	$ 164,535
2024	156,605
2025
Total	321,140
Less: effect of discounting	(14,491)
Present value of lease liabilities	$ 306,649

Schedule of Cost Component of O

Schedule of Cost Component of Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating lease cost	$ 57,755	$ 57,129
Short-term lease cost		1,634
Total lease cost	$ 57,755	$ 58,763

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ (59,274)	$ (58,535)

Leases (Details Narrative)

Leases (Details Narrative)	1 Months Ended	3 Months Ended
	Nov. 30, 2016 USD ($) ft²	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease payments		$ 59,274	$ 58,535
Alachua Facility [Member]
Lessee, Lease, Description [Line Items]
Rent expense		41,426
Maximum [Member] | Alachua Facility [Member]
Lessee, Lease, Description [Line Items]
Rent expense		13,338
Alachua Facility [Member] | Minimum [Member]
Lessee, Lease, Description [Line Items]
Rent expense		12,870
Tampa Facility [Member]
Lessee, Lease, Description [Line Items]
Rent expense		$ 16,700
Area of Real Estate Property | ft²	2,207
Operating lease payments	$ 4,944
Lease Expiration Date	Feb. 29, 2024